Champions Biotechnology, Inc., an oncology drug development
company, has announced that a Master Service Agreement with Teva Pharmaceutical
Industries has been commissioned for the testing of a novel anti-angiogenic
compound in the Champions Tumorgraft™ platform.
Anti-angiogenic compounds are designed to work by blocking
the tumor’s blood supply. There are multiple approved and experimental
anti-angiogenic compounds for colorectal, breast, and lung cancer. Teva is
developing agents in this area to help treat various forms of cancer.
Under the terms of the agreement, Champions will use its
Champions Tumorgraft™ platform to test the effectiveness of Teva’s compound in
various cancer indications to assist in further clinical development. “We
are very excited to work with Teva on this program. The use of our highly-predictive
Champions Tumorgraft™ platform will provide Teva with the data necessary for
critical drug development decisions and help focus and accelerate the
development program for this compound,” said Elizabeth Bruckheimer, Ph.D.,
Vice President of Scientific Operations, Champions Biotechnology, Inc.
